Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BDX stock price vs A: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at A's multiple
Needs A P/E.
Implied fair value · at BDX's multiple
Needs BDX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BECTON, DICKINSON AND COMPANY · implied price per share
Bear
$42.31
Base
$61.15
Bull
$85.69
AGILENT TECHNOLOGIES, INC. · implied price per share
Bear
$41.49
Base
$49.80
Bull
$60.61
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Johnson & Johnson
BDX vs JNJ
Medtronic plc
BDX vs MDT
DANAHER CORP /DE/
BDX vs DHR
STRYKER CORP
BDX vs SYK
THERMO FISHER SCIENTIFIC INC.
BDX vs TMO
ILLUMINA, INC.
BDX vs ILMN
BIO-TECHNE Corp
BDX vs TECH
BRUKER CORP
BDX vs BRKR
Azenta, Inc.
BDX vs AZTA
WATERS CORP /DE/
BDX vs WAT
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BDX can sustain faster growth while improving margins and reducing leverage toward A’s profile, then the current price offers only modest upside and could justify a selective buy; otherwise, the limited 5.1% implied upside and weaker quality metrics argue for holding rather than aggressively adding.
BDX’s current price of $176.86 sits 5.1% below the P/E-based implied price of $185.90, suggesting only a small valuation gap. The market is also not giving BDX the premium multiples seen in A, but BDX’s cheaper P/S and EV-based multiples reflect materially lower profitability and higher leverage.
Supporting Metrics
